Unusual mid-shaft fractures during long-term bisphosphonate therapy

Clinical Endocrinology

Volumn 72, Issue 2, 2010, Pages 161-168

  Odvina, Clarita V ^a   Levy, Shiri ^b   Rao, Sudhir ^b   Zerwekh, Joseph E ^a   Rao, D S ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GLUCOCORTICOID; RISEDRONIC ACID; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FEMUR FRACTURE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MORPHOMETRICS; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AGED; ALENDRONATE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS;

EID: 74549195497     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03581.x     Document Type: Article

References (40)

1. Stafford, R.S., Drieling, R.L. Hersh, A.L. (2004) National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Archives of Internal Medicine, 164, 1525 1530.
2. Liberman, U.A., Weiss, S.R., Bröll, J. et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New England Journal of Medicine, 333, 1437 1443.
3. Tonino, R.P., Meunier, P.J., Emkey, R. et al. (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism, 85, 3109 3115.
4. Black, D.M., Thompson, D.E., Bauer, D.C. et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. Journal of Clinical Endocrinology and Metabolism, 85, 4118 4124.
5. Harris, S.T., Watts, N.B., Genant, H.K. et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Journal of American Medical Association, 282, 1344 1352.
6. Reginster, J.Y., Minne, H.W., Sorensen, O.H. et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established osteoporosis. Vertebral efficacy with risedronate therapy (VERT) Study group. Osteoporosis International, 11, 83 91.
7. Bone, H.G., Hosking, D., Devogelaer, J.P. et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine, 350, 1189 1199.
8. Mellström, D.D., Sörensen, O.H., Goemaere, S. et al. (2004) Seven years of treatment with risedronate with women with postmenopausal osteoporosis. Calcified Tissue International, 75, 462 468.
9. Fleisch, H.A. (1997) Bisphosphonates: preclinical aspects and use in osteoporosis. Annals of Medicine, 29, 55 62.
10. Odvina, C.V., Zerwekh, Z.E., Rao, D.S. et al. (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. Journal of Clinical Endocrinology and Metabolism, 90, 1291 1301.
11. Schneider, J.P. (2006) Should alendronate be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics, 61, 31 33.
12. Armamento-Villareal, R., Napoli, N., Panwar, V. et al. (2006) Suppressed bone turnover during alendronate therapy for high turnover osteoporosis. New England Journal of Medicine, 355, 2048 2050.
13. Goh, S.K., Yang, K.Y., Koh, J.S.B. et al. (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy. Journal of Bone and Joint Surgery (British Volume), 89-B, 349 353.
14. Imai, K., Yamamoto, S., Anamizu, Y. et al. (2007) Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. Journal of Bone and Mineral Metabolism, 25, 333 336.
15. Cheung, R.K.H., Leung, K.K., Lee, K.C. et al. (2007) Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Medical Journal, 13, 485 489.
16. Armamento-Villareal, R., Napoli, N., Diemer, K.M. et al. (2007) Prevalence of severe suppression of bone turnover among patients with atypical osteoporotic fractures. Journal of Women's Health, 16, 1106.
17. Kwek, E.B.K., Goh, S.K., Koh, J.S.B. et al. (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury, 39, 224 231.
18. Lenart, B.A., Lorich, D.G. Lane, J.M. (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. New England Journal of Medicine, 358, 1304 1306.
19. Visekruna, M., Wilson, D. McKiernan, F.E. (2008) Severely suppressed bone turnover and atypical skeletal fragility. Journal of Clinical Endocrinology and Metabolism, 93, 2948 2952.
20. Lenart, B.A., Nevasier, A.S., Lyman, S. et al. (2008) Association of low-energy femoral shaft fractures with prolonged bisphosphonate use: a case control study. Osteoporosis International, published on line on December 9, 2008 : Doi:.
21. Sayed-Noor, A. Sjödén, G.O. (2008) Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy-a case report. Acta Orthopaedica, 79, 565 567.
22. Seeley, D.G., Browner, W.S., Nevitt, M.C. et al. (1991) Which fractures are associated with low appendicular bone mass in elderly women? Annals of Internal Medicine, 115, 837 842.
23. Stone, K., Seeley, D.H., Lui, L.Y. et al. (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results form the study of osteoporotic fractures. Journal of Bone and Mineral Research, 18, 1947 1954.
24. Han, Z.-H., Palnitkar, S., Rao, D.S. et al. (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. Journal of Bone and Mineral Research, 12, 498 508. (Pubitemid 27155209)
25. Recker, R.R., Kimmel, D.B., Parfitt, A.M. et al. (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. Journal of Bone and Mineral Research, 3, 133 144.
26. Abrahamsen, B., Eiken, P. Eastell, R. (2008) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. Journal of Bone Mineral Research, published online December 29, 2008 : Doi:.
27. Bauer, D.C., Garnero, P., Hochberg, M.C. et al. (2006) Pretreatment levels of bone turnover and antifracture efficacy of alendronate: the fracture intervention trial. Journal of Bone and Mineral Research, 21, 292 299.
28. Frost, H. (1960) Presence of microscopic cracks in vivo in bone. Henry Ford Hospital Medical Bulletin, 8, 27 35.
29. Mori, S., Harruf, R., Ambrosius, W. et al. (1997) Trabecular one volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone, 21, 521 526.
30. Schaffler, M., Choi, K. Milgrom, C. (1995) Aging and matrix microdamage accumulation in human compact bone. Bone, 17, 521 525.
31. Schaffler, M., Radin, E.L. Burr, D.B. (1989) Mechanical and morphological effects of strain rate fatigue of compact bone. Bone, 10, 207 214.
32. Keaveny, T.M., Wachtel, E.F., Guo, X.E. et al. (1994) Mechanical behavior of damaged trabecular bone. Journal of Biomechanics, 11, 1309 1318.
33. Jepsen, K. Davy, D.T. (1997) Comparison of damage accumulation measures in human cortical bone. Journal of Biomechanics, 30, 891 894.
34. Pidaparti, R.M., Akyuz, U., Naick, P.A. et al. (2000) Fatigue data analysis of canine femurs under four-point bending. Biomedical Materials and Engineering, 10, 43 50.
35. Norman, T.L., Yeni, Y.N., Brown, C.U. et al. (1998) Influence of microdamage on fracture toughness of the human femur and tibia. Bone, 23, 303 306.
36. Mashiba, T., Hirano, T., Turner, C.H. et al. (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research, 15, 613 620.
37. Mashiba, T., Turner, C.H., Hirano, T. et al. (2001) Effects of suppressed bone turnover by bisphosphonate on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone, 28, 524 531.
38. Boivin, G.Y., Chavassieux, P.M., Santora, A.C. et al. (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 27, 687 694.
39. Burr, D.B., Miller, L., Grynpas, M. et al. (2003) Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone, 33, 960 969.
40. Currey, J.D., Brear, K. Zioupos, P. (1996) The effects of aging and changes in mineral content in degrading the toughness of human femora. Journal of Biomechanics, 29, 257 260.